Nanodrugs

LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF

Absstract of: WO2024064800A2

Disclosed herein are lipid nanoparticles comprising plurality of lipids, a targeting moiety for an HIV-1 chemokine receptor, and a CRISPR nucleic acid complementary to an HIV-1 gene, pharmaceutical compositions and methods of use thereof.

LIPID NANOPARTICLES COMPRISING NUCLEIC ACIDS ENCODING THERAPEUTIC GENES AND USES IN MEDICAL METHODS

Absstract of: WO2024064206A1

This disclosure relates to lipid nanoparticles comprising nucleic acids encoding therapeutic proteins and uses in treating diseases such as cancer. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of lipid nanoparticles as reported herein comprising a vector or nucleic acid encoding peptide based anticancer agent.

ANTIVIRAL SIRNA THERAPEUTIC FOR SARS-COV-2

Absstract of: AU2023347083A1

This disclosure relates to RNA interference (RNAi) reagents for treatment of SARS-CoV-2 infection, compositions comprising same, and use thereof to treat or prevent infection by SARS- CoV-2.

標的を定めた遺伝子抑制を介して低密度リポタンパク質を低減するための組成物、系、及び方法

Absstract of: MX2025000123A

Provided in some aspects are epigenetic-modifying DNA-targeting systems, such as CRISPR-Cas/guide RNA (gRNA) systems for the transcriptional repression of genes to promote a cellular phenotype that leads to reduction of low-density lipoprotein (LDL). In some embodiments, the epigenetic-modifying DNA-targeting systems bind to or target a target site of at least one gene or regulatory element thereof that regulate LDL. In some embodiments, the systems are multiplexed systems that bind to or target a target site in at least two genes or regulatory elements thereof. Also provided herein are methods and uses related to the provided epigenetic-modifying DNA targeting systems in connection with treatments for cardiovascular disease and familial hypercholesterolemia.

FUNCTIONALIZED BIOCATALYTICAL COMPOSITIONS

Absstract of: WO2024061861A1

The present invention relates to a composition comprising a solid carrier, an enzyme or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the enzyme or the fragment thereof by embedding the enzyme or the fragment thereof, and a functional constituent immobilized on the surface of the protective layer. The present invention also relates to a method for the prevention, delay of progression or treatment of lung cancer in a subject using said composition and methods of producing said composition.

OIL-IN-WATER EMULSIONS FOR TOPICAL ADMINISTRATION AND USES THEREOF

Absstract of: WO2024062127A1

Oil-in-water Pickering emulsion comprising: an oil phase comprising a first therapeutic agent, an aqueous phase, polyester nanoparticles comprising a second therapeutic agent, wherein the oil phase is in the form of droplets and is dispersed in a continuous aqueous phase, and wherein at least a portion of the nanoparticles are localized at an interface between the oil phase and the aqueous phase, characterized in that the aqueous phase comprises hyaluronan. This new emulsion allows the topical treatment of inflammatory dermatoses such as psoriasis, atopic dermatitis or prurigo, benign skin inflammations such as inflammatory acne, scalp pathologies such asalopecia, dermo-cosmetic conditions, such as very dry irritable skin, tumor pathologies such as mycosis fungoides (indolent cutaneous T lymphoma) or cutaneous mastocytosis (accumulation and abnormal proliferation of mast cells in the dermis, with intense pruritus), and fibrosing pathologies such as keloids (raised, pruritic dystrophic scars, which have the particularity of not regressing spontaneously and of being able to extend beyond the traumatic/injured area).

LIPID NANOPARTICLE WITH NUCLEIC ACID CARGO

Absstract of: MX2025003345A

Disclosed is a lipid nanoparticle (LNP) encapsulating a nucleic acid cargo preferably comprising messenger ribonucleic acid (mRNA). The LNP comprises at least a cationic lipid fraction, and a stabilizer fraction. The stabilizer fraction preferably comprises at least one polyethylenglycol (PEG) lipid. Furthermore, the LNP comprises at least one glycerol dialkyl glycerol tetraether (GDGT) lipid, as obtained e.g. from archaea of the genus Sulfolobus, optionally among other ether lipids. Also disclosed is a pharmaceutical composition comprising the LNP, such as an mRNA vaccine.

개 CD3 및 CD20에 대한 이중특이적 항체

Absstract of: MX2025006274A

This disclosure provides a bispecific canine antigen-binding molecule comprising a first antigen binding domain or antigen-binding portion thereof that specifically binds canine CD3, and a second antigen binding domain or antigen-binding portion thereof that specifically binds canine CD20, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD3, compositions comprising the same, and methods of their use. The disclosure also provides a canine antibody or antigen-binding portion thereof that binds canine CD20, compositions comprising the same, and methods of their use.

递送治疗剂的方法和脂质组合物

Absstract of: WO2024135604A1

The object of the present invention is to provide a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells which can realize excellent delivery efficiency to organs other than the liver, and a composition containing a therapeutic agent and lipid nanoparticles which can realize excellent delivery efficiency to an organ other than the liver. The present invention provides a method for delivering a therapeutic agent to endothelial cells, mesenchymal cells, or cancer cells, which comprises administering a lipid composition to a subject, wherein the lipid composition comprises the therapeutic agent and lipid nanoparticle, and wherein the lipid nanoparticle comprises an ionizable lipid and a compound represented by formula (1) or a salt thereof. (1) wherein G1 represents -C(O)-, -OC(O)-, -O(CO)O- or -C(O)O-, LY represents a single bond, an alkylene group having 1-14 carbon atoms, a substituted alkylene group having 1-14 carbon atoms, a heteroalkylene group having 1-14 carbon atoms, and a substituted heteroalkylene group having 1-14 carbon atoms. X represents a basic functional group.

脂质纳米颗粒冻干方法和组合物

Absstract of: AU2023393613A1

The invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent, as well as a method of preparing same.

基因编辑构建体的靶向递送及其使用方法

Absstract of: WO2024112882A1

The present invention relates to compositions for effective delivery of gene editing agents to a target cell, as well as methods of use thereof for the treatment of a disease or disorder.

一种基于吡啶基卟啉的聚乙二醇化的纳米颗粒及其制备方法与应用

Absstract of: CN120381439A

本发明涉及一种基于吡啶基卟啉的聚乙二醇化的纳米颗粒及其制备方法与应用。本发明的纳米颗粒为壳核结构的球形纳米颗粒；所述壳为脂质‑聚乙二醇双层结构；所述核为基于吡啶基卟啉的铂离子型化合物；所述基于吡啶基卟啉的铂离子型化合物通过吡啶醇类配体与PtCl2(PhCN)2混合制备得到。本发明通过将铂类药物与质子化卟啉通过离子对结合解决了传统铂类药物的诸多问题，主要包括提高了铂类药物的水溶性以及对肿瘤细胞的细胞毒性作用，实现了化学疗法和PDT疗法的协同抗癌作用。材料无需复杂的制备过程，操作简便，易于封装。

环状RNA组合物

Absstract of: AU2023375897A1

Provided herein are circular RNA constructs comprising an IRES, and at least one expression sequence encoding binding molecule, compositions thereof, and methods of treatment, including for cancer and autoimmune disease. In particular, circular RNA comprising an IRES and a CD19 binder, a HER2 binder, or a BCMA binder are provided, optionally formulated with a delivery vehicle. Precursor polynucleotides comprising an IRES, and at least one expression sequence encoding a CAR construct are also described herein.

一种利用相分离实现高效降解的PROTAC及其递送方式

Absstract of: CN120383680A

本发明公开了一种高效降解目标蛋白的PROTAC及其制备和递送方法，将相分离序列与设计的双靶向分子融合，分别靶向目标蛋白以及蛋白酶体，实现PROTAC与目标蛋白的相分离，从而实现目标蛋白的高效降解。通过LNP包封mRNA也实现了PROTAC的递送，同样可以在细胞内高效降解目标蛋白，这也为肽类或蛋白类PROTAC向人体内的递送提供了一种途径。

用于器官选择性递送核酸药物的类脂质分子、类脂质纳米颗粒及其应用、类脂质纳米颗粒-核酸复合物及其制备方法

Absstract of: CN120383729A

本发明涉及生物医药技术领域，尤其涉及一种用于器官选择性递送核酸药物的类脂质分子、类脂质纳米颗粒及其应用、类脂质纳米颗粒‑核酸复合物及其制备方法。本发明提供的类脂质分子是由聚乙烯亚胺与芳基丙烯酸酯发生迈克尔加成反应得到，合成方法简单安全，反应条件温和，成本低；所述类脂质纳米颗粒按质量百分比计由如下组分组成：类脂质分子30～80％，甾醇5～50％，聚乙二醇‑脂质5～40％，辅助脂质5～50％。本发明的优点在于通过调节类脂质分子自身的化学结构实现了其类脂质纳米颗粒在受试生物体内对核酸药物的器官选择性递送。

一种载药纳米粒子及金属多酚网络介导的可食源性组装体

Absstract of: CN120381531A

本发明涉及载药粒子技术领域，尤其涉及一种载药纳米粒子及金属多酚网络介导的可食源性组装体，将天然硫化物包覆在含有介孔结构的碳酸钙中形成所述载药纳米粒子，并将载药纳米粒子的外层包裹上具有金属‑多酚网络结构的纳米涂层，得到金属多酚网络介导的可食源性组装体，用于制备治疗酒精损伤的药物，所述药物有助于减轻酒精造成的组织损伤和行为障碍。

一种可溶性纳米微针及其制备方法和应用

Absstract of: CN120381429A

本发明公开了一种可溶性纳米微针及其制备方法和应用，涉及纳米微针领域。本发明在制备可溶性纳米微针时，将吡咯、苯甲醛、对羟基苯甲醛、1,6‑二溴己烷反应制得季铵化卟啉；将聚乳酸‑羟基乙酸共聚物、季铵化卟啉通过乳液法制得载药纳米微球；再将聚乙烯醇溶液、载药纳米微球通过模板法制得。本发明制备的可溶性纳米微针具有良好的药物释放效果，药物利用率高，且刺激性低。

一种用于肿瘤靶向的自触发蛋白质水解及RNA干扰的纳米粒子及其制备方法与应用

Absstract of: CN120381441A

本发明公开了一种用于肿瘤靶向的自触发蛋白质水解及RNA干扰的纳米粒子及其制备方法与应用，属于生物医药技术领域。本发明的纳米粒子以铁蛋白为载体，其内包裹有能够上调线粒体铁转运蛋白的siRNA，表面修饰有E3连接酶配体和肿瘤靶向肽，其制备方法包括：通过Click反应将E3连接酶配体和肿瘤靶向肽修饰在铁蛋白表面；利用铁蛋白的pH依赖性解聚/重组特性，将siRNA装载到铁蛋白载体中，获得用于肿瘤靶向的自触发蛋白质水解及RNA干扰的纳米粒子。本发明的纳米粒子能有效躲避肝脏的清除，有效富集在肿瘤部位，通过破坏肿瘤细胞线粒体内铁稳态，诱导肿瘤细胞死亡，进而激活强大的抗肿瘤免疫，其可用于制备抗肿瘤药物。

一种工程化强效树突状细胞疫苗及其制备方法与应用

Absstract of: CN120381516A

本发明公开了一种工程化强效树突状细胞疫苗及其制备方法与应用，利用纳米级抗原递送的方式，将肿瘤抗原与阳离子脂质体相融合，借助阳离子脂质电荷相互作用破坏溶酶体膜的稳定性，使部分抗原逃逸到细胞质中通过MHC I途径交叉呈递，给予DC以激活细胞免疫应答的能力对抗肿瘤；另一方面，通过合成免疫学的方法赋予DC以T细胞导向性，首先在DC表面修饰叠氮基团N3，在T细胞特异性抗体上修饰二苯并环辛炔基团DBCO，通过N3与DBCO的环加成反应将T细胞特异性抗体偶联到成熟DC表面，增加DC和T细胞接触的机会和持续时间，促进DC‑T细胞的相互作用和信号传递；两种机制的联合可克服现有DC疫苗反应率低的问题，实现抗肿瘤免疫响应的最大化。

一种含有Survivin siRNA和ZnO的pH敏感的靶向纳米载药系统

Absstract of: CN120381440A

本发明公开了具有pH响应性和肿瘤靶向性的siRNA递送载体CCM‑CS/ZnO@siSurvivin，公开了其制备方法，公开了其形态、结构等理化性质，公开了其包封率、释药行为，公开了其细胞摄取效率、肿瘤靶向能力、溶酶体逃逸能力、基因沉默效率、促凋亡能力、肿瘤细胞生长抑制能力，公开了Survivin siRNA和ZnO协同抗肿瘤能力，进一步公开了其体内靶向性以及抑制BALB/c荷瘤裸鼠肿瘤生长的作用和体内安全性。进而阐明了该靶向递送载体在肿瘤的基因治疗领域具有重要的应用。

세포 표적화를 위한 스텔스 지질 나노입자 조성물

Absstract of: AU2023406483A1

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types,

Sistema lipídico nanoestructurado que contiene besifloxacina, composición farmacéutica y usos

Absstract of: WO2024098127A1

The present invention describes nanostructured lipid systems containing the antibiotic besifloxacin and the application thereof in the treatment and prevention of bacterial eye infections. Besifloxacin, an antibiotic with low aqueous solubility, is encapsulated in a nanostructured lipid system comprising a solid lipid, a liquid lipid, a surfactant and a co-surfactant. Optionally, the system of the invention can be additionally coated with an antibacterial cationic agent. The nanostructured lipid system according to the invention allows the topical administration of besifloxacin in the eyes and gives the drug a longer retention time on the surface of the eye. Furthermore, the system described herein is designed using industrially applicable methods and remains stable under storage conditions for at least 90 days, so it can be readily reproduced on an industrial scale.

Arnm que codifica una partícula similar al virus de la gripe

Absstract of: MX2025006877A

The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.

Nanoemulsions for drug delivery

Absstract of: KR20250113560A

본 발명은 건강기능 향상과 질병 치료에 다양하게 사용할 수 있는 신규 나노에멀젼의 발명에 관한 것으로, 치료용 약물이나 생리활성 기능성 물질을 나노크기의 나노에멀젼 내부에 충전하고 세포나 조직의 내부로 활성물질을 전달하는 용도로서 의약품, 화장품 및 기능성 식품 등 다양한 분야에 활용할 수 있다.

一种基于多酚氧化偶联自组装的pH响应性口服纳米药物及其制备方法和应用

Nº publicación: CN120360965A 25/07/2025

Applicant:

四川大学

Absstract of: CN120360965A

本发明公开了一种基于多酚氧化偶联自组装的pH响应性口服纳米药物及其制备方法和应用。该纳米药物设计简单高效，本发明所述的纳米药物是基于多酚在酸性介质中通过氧化剂介导的氧化偶联自组装，提供了一种耐酸不耐碱的pH响应性口服递送载体。通过溶剂转换介导的解组装‑重组装作用，高效负载疏水性药物，制备得到口服纳米药物。本纳米策略极大的提高了疏水性药物的载药率，载药量高达50％。同时避免了纳米药物被恶劣的胃生理环境破坏，靶向肠道递送。基于生物活性的多酚载体与药物之间的双重抗炎抗氧化作用，该口服纳米药物能够作为优异的多功能药物制剂通过协同作用预防或治疗炎症性肠病。